All Episodes

April 8, 2025 30 mins

In this episode of Curing with Sound, Zhen Xu, PhD, the Li Ka Shing Endowed Professor of Biomedical Engineering at the University of Michigan, discusses histotripsy. Dr. Xu and her colleagues developed histotripsy, the first noninvasive, nonthermal ultrasound ablation technique that received FDA approval for liver tumor treatment in 2023. Her work has led to multiple clinical trials on histotripsy treatment for malignant and benign tumors. 

Dr. Xu shares the 20-year journey from initial discovery to clinical application and highlights histotripsy's remarkable ability to mechanically break down targeted tissue without incisions or radiation. She also recounts inspiring patient stories from clinical trials, including patients who experienced no pain and returned to normal activities immediately after treatment. 

  • Regulatory Approval: In October 2023, the FDA cleared HistoSonics’ novel therapy platform, Edison™, to treat liver tumors. Edison™ uses histotripsy to noninvasively destroy liver tissue. This is the first time the use of histotripsy has earned regulatory approval worldwide.
  • The Science Behind Histotripsy: Dr. Xu explains how histotripsy uses focused ultrasound pulses to rapidly expand and collapse microbubbles that break down targeted cells with remarkable precision.
  • Future Directions: Dr. Xu envisions continued expansion of histotripsy applications over the next five years, including wider adoption for liver tumors, regulatory approvals for additional indications, and the development of new platforms for brain and shallow tumor treatments.

Histotripsy Lab: histotripsy.umich.edu Connect on Linked In: Dr. Zhen Xu

EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances. 

Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation. 

FUSF SOCIAL MEDIA

FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

Mark as Played

Advertise With Us

Popular Podcasts

NFL Daily with Gregg Rosenthal

NFL Daily with Gregg Rosenthal

Gregg Rosenthal and a rotating crew of elite NFL Media co-hosts, including Patrick Claybon, Colleen Wolfe, Steve Wyche, Nick Shook and Jourdan Rodrigue of The Athletic get you caught up daily on all the NFL news and analysis you need to be smarter and funnier than your friends.

On Purpose with Jay Shetty

On Purpose with Jay Shetty

I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!

Dateline NBC

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2025 iHeartMedia, Inc.